EUDA Health Holdings Limited (NASDAQ: EUDA) was upgraded by analysts at Greenridge Global to a "strong-buy" rating.
EUDA Holdings and Guangdong Cell Biotech Explore Potential Strategic Partnership to Advance Biotechnology Innovation [Yahoo! Finance]
EUDA Holdings and Guangdong Cell Biotech Explore Potential Strategic Partnership to Advance Biotechnology Innovation
EUDA Health Holdings First Half 2024 Earnings: US$0.59 loss per share (vs US$0.40 loss in 1H 2023) [Yahoo! Finance]
Euda Health files for $100M mixed securities shelf [Seeking Alpha]